Cellectar Biosciences
CLRB
20 hedge funds and large institutions have $3.08M invested in Cellectar Biosciences in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
5% more funds holding
Funds holding: 19 → 20 (+1)
1.18% less ownership
Funds ownership: 17.59% → 16.41% (-1.2%)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
72% less capital inflows, than outflows
Capital inflows: $70.1K | Capital outflows: $252K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$49.4K |
| 2 |
Renaissance Technologies
New York
|
+$10.6K |
| 3 |
1900 Wealth Management
San Antonio,
Texas
|
+$9.6K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$433 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$96 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$190K |
| 2 |
Worth Venture Partners
Fort Lee,
New Jersey
|
-$37K |
| 3 |
Bank of New York Mellon
New York
|
-$17.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.63K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.44K |
CLRB Hedge Fund Activity: Q2 2023 in Review
20 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2023, worth a combined $3.08M — up 27% from $2.43M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CLRB positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $49.4K. The largest seller was AIGH Capital Management, cutting an estimated $190K.
- 20 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2023, up from 19 in Q1 2023.
- Funds reported $3.08M of Cellectar Biosciences stock for Q2 2023, up 27% quarter-over-quarter.
- 2 funds opened new Cellectar Biosciences positions in Q2 2023 and 1 closed out, a net change of +1 holder.
- The largest Cellectar Biosciences buyer in Q2 2023 was Citadel Advisors, an estimated $49.4K added.
- The largest Cellectar Biosciences seller in Q2 2023 was AIGH Capital Management, an estimated $190K sold.
Based on aggregated 13F filings for Q2 2023.